secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001641172-25-021595
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO and two directors resign; interim CEO appointed; director cites irreconcilable differences
--------------------------------------------------------------------------------

- Michael Howe steps down as CEO and Director effective July 24, 2025; no disagreement with company.
- Kraig Higginson, Chairman, appointed Interim CEO; company searching for permanent CEO.
- Gary Stein resigns as independent Director and Audit Committee chair; Howard Doss succeeds him.
- Barbara Sher resigns as director citing irreconcilable differences with company policies and direction.
- No disagreements cited for Howe or Stein; Sher's resignation letter provided to company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000164117225021595/0001641172-25-021595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000164117225021595/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-021595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer